(City)

(State)

(Zip)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 32350104

Estimated average burden hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

			6(a) of the Securities Exchar ne Investment Company Act		1934			
Name and Address of Reporting Person* Shah Pratik	2. Date of Ever Requiring State (Month/Day/Ye 11/08/2022	ement	3. Issuer Name and Ticker or Trading Symbol ARS Pharmaceuticals, Inc. [SPRY]					
(Last) (First) (Middle) C/O ARS PHARMACEUTICALS, INC.			4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner			5. If Amendment, Date of Original Filed (Month/Day/Year)		
11682 EL CAMINO REAL, SUITE 120			Officer (give title below)	Other (specify below)		6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person		
(Street) SAN DIEGO CA 92130						X	Form filed Reporting	by More than One Person
(City) (State) (Zip)								
Та	ble I - Non-D	erivativ	ve Securities Benefi	cially O	wned			
1. Title of Security (Instr. 4)			. Amount of Securities Beneficially Owned (Instr.)	3. Owner Form: I (D) or II (I) (Inst	Direct ndirect		ture of Indire ership (Instr.	
			Securities Beneficia					
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of S Underlying Derivative So (Instr. 4)			cise Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Expiration Exercisable Date		Title	Amount or Number of Shares	Derivative Security		or Indirect (I) (Instr. 5)	3)
Name and Address of Reporting Person* Shah Pratik								
(Last) (First) (Mic C/O ARS PHARMACEUTICALS, IN 11682 EL CAMINO REAL, SUITE 12								
(Street) SAN DIEGO CA 921	30							
(City) (State) (Zip)							
1. Name and Address of Reporting Person* Pratik Shah Living Trust dated 2011	<u>June 15,</u>							
(Last) (First) (Mic C/O ARS PHARMACEUTICALS, IN 11682 EL CAMINO REAL, SUITE 12								
(Street) SAN DIEGO CA 921	30							

Explanation of Responses:
Remarks:

No securities are beneficially owned.

/s/ Kathleen Scott, Attorney-in-Fact 11/10/2022

/s/ Kathleen Scott, Attorney-in-Fact 11/08/2022

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Richard Lowenthal, Kathleen Scott and Justin Chakma of ARS Pharmaceuticals, Inc. (the "Company"), signing individually, the undersigned's true and lawful attorney-in-fact and agent to:

- (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact shall no longer be employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of October, 2022.

/s/ Pratik Shah, Ph.D.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 2nd day of November, 2022.

/s/ Pratik Shah, Ph.D. Trustee, The Pratik Shah Living Trust June 15, 2011